| Literature DB >> 35582288 |
Sreecanth S Raja1, Robert G Batey2, Suzanne Edwards3, Hein H Aung2.
Abstract
BACKGROUND: Liver cirrhosis and hepatocellular carcinoma (HCC) are highly prevalent in Australia's Northern Territory. Contributing factors include high levels of alcohol consumption, viral hepatitis and metabolic syndrome. Rural Aboriginal residents form a significant proportion of the Central Australian population and present a challenge to traditional models of liver care. HCC surveillance and variceal screening are core components of liver cirrhosis management. AIM: To assess participation in HCC and variceal surveillance programmes in a Central Australian liver cirrhosis patient cohort.Entities:
Keywords: Alcoholic liver disease; Central australia; Cirrhosis; Hepatocellular carcinoma; Viral hepatitis
Year: 2022 PMID: 35582288 PMCID: PMC9055197 DOI: 10.4254/wjh.v14.i3.559
Source DB: PubMed Journal: World J Hepatol
Descriptive statistics for all data and all variables in the study
|
|
|
| Age at diagnosis, years–mean ± SD | 50.7 (11.9) |
|
| |
| Female | 82 (42.5%) |
| Male | 111 (57.5%) |
| Aboriginal | 154 (79.8%) |
|
| |
| Alice Springs | 58 (30.1%) |
| Alice Springs township | 31 (16.1%) |
| Rural | 104 (53.9%) |
|
| |
| IVDU | 15 (7.9%) |
| Hazardous alcohol intake | 137 (71.4%) |
| Obesity | 63 (35.6%) |
|
| |
| A | 94 (50%) |
| B | 71 (37.8%) |
| C | 23 (12.2%) |
| MELD score–median (IQR) | 10 (8, 18) |
| Decompensating event triggering admission | 58 (30.4%) |
|
| |
| Alcohol | 96 (49.7%) |
| Hepatitis B | 22 (11.4%) |
| NAFLD | 11 (5.7%) |
| Hepatitis C | 9 (4.7%) |
| Cardiac cirrhosis | 6 (3.1%) |
| Cryptogenic | 6 (3.1%) |
| Autoimmune hepatitis | 2 (1%) |
| Biliary diseases | 2 (1%) |
| NAFLD + Alcohol | 5 (2.6%) |
| Hepatitis C + Alcohol | 11 (5.7%) |
| Hepatitis B + Alcohol | 18 (9.3%) |
| Cardiac cirrhosis + NAFLD | 3 (1.6%) |
| Hepatitis B + NAFLD | 2 (1.0%) |
| Participation in variceal surveillance | 75 (41.9%) |
| Participation in HCC surveillance | 32 (20.3%) |
| Development of HCC during study period | 29 (15.0%) |
|
| 95 (49.5%) |
|
| 12 (6.4%) |
NAFLD: Non-Alcoholic fatty liver disease; HCC: Hepatocellular carcinoma; MELD: Model for End-stage Liver Disease; IVDU: Intravenous drug use.
Comparison of aboriginal vs non-aboriginal patients
|
|
|
|
|
| Total number | 154 (79.8%) | 39 (20.2%) | |
| Age at diagnosis–mean ± SD | 48.4 (11.1) | 59.9 (10.9) | < 0.001 |
| Gender–Female | 76 (49.4%) | 6 (15.4%) | < 0.001 |
|
| < 0.001 | ||
| Alice Springs | 24 (15.6%) | 34 (87.2%) | |
| Alice Springs camp | 31 (20.1%) | 0 | |
| Rural | 99 (64.3%) | 5 (12.8%) | |
|
| |||
| IVDU | 2 (1.3%) | 13 (33.3%) | < 0.001 |
| Hazardous alcohol intake | 111 (72.6%) | 26 (66.7%) | 0.468 |
| Obesity | 48 (34.5%) | 15 (38.4%) | 0.573 |
|
| 0.091 | ||
| A | 69 (46.3%) | 25 (64.1%) | |
| B | 62 (41.6%) | 9 (23.1%) | |
| C | 18 (12.1%) | 5 (12.8%) | |
|
| 11 (8, 20) | 10 (8, 12) | 0.026 |
| Decompensating event triggering admission | 45 (29.4%) | 13 (34.2%) | 0.565 |
|
| < 0.001 | ||
| Alcohol | 86 (55.8%) | 10 (25.6%) | |
| Hepatitis B | 20 (13.0%) | 2 (5.1%) | |
| NAFLD | 12 (7.8%) | 2 (5.1%) | |
| Hepatitis C | 1 (0.7%) | 8 (20.5%) | |
| Cardiac cirrhosis | 4 (2.6%) | 2 (5.1%) | |
| Cryptogenic | 4 (2.6%) | 2 (5.1%) | |
| Autoimmune hepatitis | 1 (0.7%) | 1 (2.6%) | |
| Biliary diseases | 0 | 2 (5.1%) | |
| Hepatitis B + Alcohol | 18 (11.7%) | 0 | |
| NAFLD + Alcohol | 5 (3.3%) | 0 | |
| Hepatitis C + Alcohol | 1 (0.7%) | 10 (25.6%) | |
| Hepatitis B + NAFLD | 2 (1.3%) | 0 | |
| Variceal surveillance | 24 (17.8%) | 11 (34.4%) | 0.002 |
| HCC surveillance | 21 (16.7%) | 11 (34.4%) | 0.038 |
| Development of HCC | 21 (13.6%) | 8 (20.5%) | 0.283 |
|
| 63 (41.2%) | 32 (84.1%) | < 0.001 |
|
| 5 (3.3%) | 7 (18.9%) | < 0.001 |
NAFLD: Non-Alcoholic fatty liver disease; HCC: Hepatocellular carcinoma; MELD: Model for End-stage Liver Disease; IVDU: Intravenous drug use.
Unadjusted and adjusted binary logistic models of hepatocellular carcinoma surveillance versus Aboriginal status
|
|
|
|
|
|
|
| |
| Yes | No | Univariate | Multivariable | ||||
| Aboriginal status-Yes | 18 | 95 | Yes | 0.31 (0.13, 0.77) | 0.011 | 0.29 (0.10, 0.87) | 0.028 |
| Age-mean ± SD | 51.7 (10.9) | 49.4 (10.8) | 1.02 (0.98, 1.06) | 0.308 | 1.00 (0.95, 1.04) | 0.866 | |
| Gender–Male | 18 | 64 | Female | 0.80 (0.35, 1.84) | 0.398 | 1.10 (0.45, 2.71) | 0.838 |
|
| 0.930 | 0.950 | |||||
| A | 18 | 65 | A | 1.18 (0.51, 2.74) | 0.694 | 0.97 (0.40, 2.34) | 0.942 |
| B | 11 | 47 | |||||
| Residence | 0.026 | ||||||
| Alice Springs | 14 | 27 | AS | 11.41 (1.39, 93.66) | 0.023 | ||
| Alice Springs camps | 1 | 22 | AS | 2.37 (1.00, 5.64) | 0.05 | ||
| Rural | 14 | 64 | AST | 0.21 (0.03, 1.67) | 0.14 | ||
| See specialist liver clinic–Yes | 26 | 52 | Yes | 10.17 (2.91, 35.52) | < 0.001 | ||
AS: Alice springs; ASC: Alice springs camps; AST: Aspartate aminotransferase.
Unadjusted and adjusted binary logistic models of Variceal surveillance
|
|
|
|
|
|
|
| |
| Yes | No | Univariate | Multivariable | ||||
| Aboriginal Status-Yes | 51 | 90 | Yes | 0.31 (0.14, 0.65) | 0.002 | 0.29 (0.12, 0.69) | 0.005 |
| Age-mean ± SD | 51.9 (11.6) | 49.2 (11.2) | 1.02 (0.99, 1.04) | 0.116 | 1.01 (0.98, 1.04) | 0.621 | |
| Gender–Male | 43 | 59 | Female | 1.00 (0.55, 1.82) | 0.995 | 1.36 (0.70, 2.63) | 0.358 |
|
| 0.930 | 0.950 | |||||
| A | 39 | 51 | A | 1.13 (0.60, 2.15) | 0.703 | 0.90 (0.45, 1.76) | 0.750 |
| B | 27 | 40 | A | 1.05 (0.39, 2.86) | 0.922 | 0.96 (0.34, 2.71) | 0.941 |
| C | 8 | 11 | B | 0.93 (0.33, 2.61) | 0.888 | 1.07 (0.37, 3.13) | 0.900 |
| Residence | 0.002 | ||||||
| Alice Springs | 33 | 20 | AS | 4.03 (1.55, 10.47) | 0.004 | ||
| Alice Springs camps | 9 | 22 | AS | 3.05 (1.52, 6.13) | 0.002 | ||
| Rural | 33 | 61 | AST | 0.76 (0.31, 1.83) | 0.535 | ||
| See specialist liver clinic–Yes | 54 | 39 | Yes | 4.22 (2.22, 8.02) | < 0.001 | ||
AS: Alice Springs; ASC: Alice Springs camps; AST: Aspartate aminotransferase.